Skip to main content
. Author manuscript; available in PMC: 2011 Jun 20.
Published in final edited form as: Virology. 2010 Apr 9;402(1):135–148. doi: 10.1016/j.virol.2010.03.009

Figure 8. Arginine at position 11 within the V3 region influences the efficiency of CCR5 use by 89.6 and coreceptor preference on CD4+ lymphocytes.

Figure 8

The amino acids of envelope V3 regions of 89.6 and C2-16 are shown, along with the 89.6 R306S and C2-16 S306R mutations, which correspond to position 11 of the V3 domain (A). Affinofile cells expressing a fixed level of CD4 and differing levels of CCR5 were infected with wild-type and mutant 89.6 and C2-16 luciferase pseudotype viruses. The results are shown as the luciferase levels at each CCR5 density normalized to infection levels on cells expressing the maximum density of CCR5 (B). PHA stimulated CD4+ lymphocytes were infected with wild-type and mutant 89.6 and C2-16 luciferase pseudotype viruses in the presence or absence of AMD3100, Maraviroc or a combination of both inhibitors. The results are presented as the RLUs measured from cell lysates 4 days after infection (C).